ArticleMultiple sclerosis journal - experimental, translational and clinical
Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset.
Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Graves' orbitopathy following Alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights.Thyroid research · 2025Review
- Brain age gap as a predictive biomarker that links aging, lifestyle, and neuropsychiatric health.Communications medicine · 2025Article
- Clinical management of alemtuzumab-induced autoimmune thyroid diseases: a narrative review.European thyroid journal · 2025Review
- Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis.Neurology and therapy · 2024Article
- Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.Journal of neurology · 2024Observational
- Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study.Clinical and experimental medicine · 2023Article
- Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.Journal of endocrinological investigation · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune thyroid disease (AITD) occurs in 40%-50% of alemtuzumab-treated persons with multiple sclerosis (pwMS), most of whom will develop Graves' Disease (GD).
objectiveTo explore contributory factors for alemtuzumab-related AITD in pwMS.
methodsA retrospective patient chart review was performed.
resultsSixteen out of 52 (30.8%) pwMS developed AITD. GD occurred in 56.3% (
conclusionAlemtuzumab-induced reconstitution GD may result from early and increased cross-reactivity between antigens common to the brainstem and thyroid, or presence of shared Human Leukocyte Antigen (HLA) alleles that determine brainstem and thyroid involvement. We suggest cautious use of alemtuzumab in younger (≤32 years) pwMS with early brainstem involvement, especially those actively planning pregnancy, where alternative therapies are readily available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.